GE Healthcare diagnostic pharmaceuticals and by-product reuse
Published December 1, 2022; updated March 23, 2026; estimated reading time 2 minutes. Page status: available. Listed under Health and life science / Biopharma and Circular economy.
GE Healthcare manufactures contrast agents used in radiological imaging. These agents are injected before scans to improve image contrast, helping radiologists identify injuries or disease and inform treatment. The article says GE Healthcare’s contrast media or molecular imaging agents are used to image about three patients per second worldwide, based on internal company data.
The company estimates demand for imaging agents is increasing by about 5% annually, attributed to population aging and wider access to healthcare.
The article describes manufacturing by-products as a disposal challenge. Over a five-year period, automation at the Lindesnes facility doubled its production capacity. Lindesnes performs the first manufacturing stage; material then goes to another GE Healthcare site for finishing and bottling before delivery.
GE Healthcare was developing technology to convert manufacturing by-products into saleable products. It also described a hospital and clinic return programme for unused product, with the aim of reprocessing and reusing it, recovering more material over the product lifecycle and reducing demand for raw materials.
The article gives a 2017 contrast-media market value of approximately USD 5 billion. It says GE Healthcare had manufacturing facilities in Norway, Ireland and China, distributed products to more than 130 countries, and served over 90 million patients annually. These are figures reported in the article, not independently verified current figures.
Related UN Sustainable Development Goals shown: 3, 9 and 12. The page’s footnotes attribute the patient figure to internal data, market information to external sources, and supply-chain information to supply-chain data.
Public contact modal names Cathrine Thomassen (CEO, GE Healthcare Norway) and Rolf Myrvold (Innovation and Development Director). Myrvold’s listed email is rolf.myrvold@ge.com; a phone-number reveal control is present but collapsed. Company listing: GE HEALTHCARE AS, Nycoveien 1, 0485 Oslo, Norway; gehealthcare.com/en/global-gateway.
Public phone number revealed by the page control on 8 October 2026: +47 948 68 975 (Rolf Myrvold, Innovation and Development Director).